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Abstract 
Common variable immunodeficiency (CVID) is the most frequent symptomatic primary antibody deficiency in adult-
hood and is characterized by the marked reduction of IgG and IgA serum levels. Thanks to the successful use of poly-
valent immunoglobulin replacement therapy to treat and prevent recurrent infections, non-infectious complications, 
including autoimmunity, polyclonal lymphoproliferation and malignancies, have progressively become the major 
cause of morbidity and mortality in CVID patients. The management of these complications is particularly challeng-
ing, often requiring multiple lines of immunosuppressive treatments. Over the last 5–10 years, the anti-CD20 mono-
clonal antibody (i.e., rituximab) has been increasingly used for the treatment of both autoimmune and non-malignant 
lymphoproliferative manifestations associated with CVID. This review illustrates the evidence on the use of rituximab 
in CVID. For this purpose, first we discuss the mechanisms proposed for the rituximab mediated B-cell depletion; then, 
we analyze the literature data regarding the CVID-related complications for which rituximab has been used, focusing 
on autoimmune cytopenias, granulomatous lymphocytic interstitial lung disease (GLILD) and non-malignant lym-
phoproliferative syndromes. The cumulative data suggest that in the vast majority of the studies, rituximab has proven 
to be an effective and relatively safe therapeutic option. However, there are currently no data on the long-term effi-
cacy and side effects of rituximab and other second-line therapeutic options. Further randomized controlled trials are 
needed to optimize the management strategies of non-infectious complications of CVID.
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Introduction
Rituximab (RTX) is a monoclonal antibody (IgG1k) that 
specifically targets the transmembrane protein CD20 
expressed on pre-B and mature B lymphocytes [1–3]. 
Binding of RTX to its receptor results in significant deple-
tion of B-cells in lymphoid tissues and peripheral blood 
by different mechanisms, including apoptosis, comple-
ment-dependent cytotoxicity, and antibody-dependent 
cytotoxicity [4–6]. Since hematopoietic stem cells do not 
express CD20, one course of treatment with rituximab is 
followed by B-cell repopulation of the peripheral blood 
starting usually within 6 to 9  months [7]. However, a 
subset of RTX-treated subjects develop prolonged B-cell 
deficiency and severe hypogammaglobulinemia requiring 
long-life immunoglobulin replacement [8–10].
RTX was first approved by the FDA in 1997 and by the 
EMA in 1998 for the treatment of relapsed or refractory, 
CD20-positive, B-cell, low-grade or follicular non-Hodg-
kin’s lymphoma [11]. In the following two decades, the 
use of RTX has progressively expanded to include, also 
with off-label indications, an increasing number of auto-
immune diseases [12–15] (i.e., rheumatoid arthritis, anti-
neutrophil cytoplasmic-associated vasculitis, systemic 
sclerosis, immune thrombocytopenia, etc.) and the EBV-
related lymphoproliferative syndromes associated with 
bone marrow transplantation [16, 17].
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Several studies reported the successful use of rituximab 
for the treatment of autoimmune and lymphoproliferative 
manifestations associated with primary immunodeficien-
cies, and in particular with common variable immuno-
deficiency (CVID) [18–20]. CVID is the most frequent 
severe antibody deficiency in adulthood and is character-
ized by the reduction of serum immunoglobulin levels 
(namely IgG and IgA) and the impairment of antibody 
production in response to pathogens and vaccines [21, 
22]. This may be due either to an intrinsic defect of B-cell 
development or to a disrupted cross-talk between B and 
T cells [23, 24]. Beyond the impairment of B-cell func-
tions, a number of other immune alterations have been 
described in CVID patients. Together, these contribute 
to the establishment of a complex immune dysregulation 
including naive T or NK deficiency, expansion of specific 
B-cell-subpopulations (i.e., CD21low and transitional 
B-cells), monocyte/macrophage activation, Th1 imbal-
ance of T-helper follicular cells (TFH) associated with 
a IFN-γ driven inflammation and neutrophil-mediated 
T-cell suppression [25–35]. According to the heterogene-
ity of the immunological alterations, CVID patients pre-
sents a wide spectrum of clinical manifestations including 
infections, inflammatory and autoimmune diseases, and 
malignancies (cancer and lymphoma) [36–41]. The het-
erogeneity of the clinical picture makes CVID diagnosis 
challenging, thus contributing to the establishment of 
a significant diagnostic delay that affects both the long-
term outcome and the quality of life of CVID patients 
[42–44]. Therefore, different population-based screen-
ing approaches have been recently introduced in the 
clinical practice to shorten diagnostic delay and improve 
long-term outcome [45, 46]. The mainstay of treatment 
of CVID is immunoglobulin replacement therapy (IgRT). 
Although immunoglobulin therapy is also used at higher 
dosage in a wide range of autoimmune and inflammatory 
conditions for its immunomodulatory effects [47], the 
main indication of this treatment is the lifelong replace-
ment therapy of antibody deficiency to prevent and treat 
recurrent infections [48]. New immunoglobulin purifica-
tion and stabilization methods have been developed thus 
allowing the administration of higher volumes and higher 
concentrations of immunoglobulins via both the intrave-
nous and the subcutaneous route [49–55].
Thanks to the successful use of IgRT to treat bacte-
rial infections, autoimmune diseases and malignancies 
have progressively become the major cause of morbidity 
and mortality in CVID patients [56–58]. CVID-related 
autoimmune and lymphoproliferative complications are 
poorly understood from the pathogenetic point of view 
and therefore difficult to manage [59]. Interestingly, in a 
large USA cohort the risk of death was 11 times higher 
for CVID patients with one or more non-infectious 
complication than for subjects who had infections only 
[56]. As consequence, a number of immunosuppressive 
protocols, which had been traditionally considered con-
traindicated in immunodeficiency patients over the last 
decades, have been increasingly used to treat autoim-
mune diseases and non-malignant lymphoproliferative 
manifestations associated with CVID [60, 61].
With the increasing evidence of effectiveness in several 
autoimmune diseases, also RTX has been progressively 
included in the therapeutic strategies for the non-infec-
tious complications of CVID [19, 62–64]. Although 
the use of a B-cell depleting monoclonal antibody in a 
humoral immune deficiency may appear paradoxical, 
the heterogeneous pathogenesis of CVID, characterized 
by a complex immune dysregulation beyond the sim-
ple impairment of antibody production, could explain 
the potential efficacy of rituximab in CVID. Although 
no large randomized controlled trials have been con-
ducted, several case reports, small series and cohort 
studies investigated the outcomes of RTX in CVID in last 
15 years.
This review summarizes the evidence available on the 
use of rituximab in CVID. For this purpose, first we will 
discuss the mechanisms of action of RTX, focusing on the 
effects on the various immune cells; then, we will analyze 
the data available for the CVID-related complications for 
whom RTX has been used, namely autoimmune cytope-
nias, granulomatous lymphocytic interstitial lung disease 
(GLILD) and non-malignant lymphoproliferation.
Mechanisms of action of rituximab
Multiple mechanisms have been proposed to explain 
the efficacy of RTX in autoimmune diseases and non-
malignant lymphoproliferation. These effector mecha-
nisms may act individually or collectively and are only 
in part ascribable to B-cell depletion. RTX depletes B 
cells primarily through three different mechanisms: 
antibody-dependent cell-mediated cytotoxicity (ADCC), 
complement-mediated cytotoxicity (CMC) and induction 
of apoptosis (Fig. 1) [65]. Among these, ADCC and CMC 
seem to be the most accountable for the B-cell depleting 
effect of RTX in vivo [66].
RTX is an IgG1 monoclonal antibody, which can acti-
vate the complement cascade, leading to 3 remarkable 
effects: (a) the generation of anaphylotoxins (e.g. C5a, 
C3a) that amplify the recruitment of effector cells; (b) 
the formation of a membrane attack complex (MAC) 
that results in the direct cell lysis; and (c) the libera-
tion of cell cleavage fragments that act as opsonins [67, 
68]. However, the differential depleting-effect of RTX 
to B-cells may depend on individual factors, as the 
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expression level of the complement regulatory proteins 
CD46, CD55 and CD59 [69].
The relevance of ADCC for the in  vivo response to 
RTX has been confirmed by the genetic analysis of 
Fc receptor polymorphisms in populations of treated 
patients, where FcγRIIIA-158 polymorphisms were 
shown to increase RTX-induced ADCC and improve 
clinical outcome [70]. This finding supports the 
hypothesis that the ADCC is the most important effect 
exerted by RTX [71, 72]. Consistent with this evidence, 
RTX was demonstrated to cause polarization of CD20, 
intercellular adhesion molecule 1 (ICAM-1), myosin, 
and the microtubule organizing center (MTOC), thus 
inducing the preferential cell-killing by effector NK 
cells [73]. However, several other immune cells, includ-
ing polymorphonuclear cells and macrophages, express 
activating Fcγ receptors. Similar to ADCC, opsonized 
cells activate FcγRs on the phagocyte surface, resulting 
in an antibody-dependent cell-mediated phagocytosis 
(ADCP). Also, phagocytes may play an important role 
in the clearance of apoptotic B cells after RTX treat-
ment [74].
B-cell depletion in peripheral blood after RTX treat-
ment is higher than 99% [75]. However, this could not 
reflect the depletive effect in lymphoid tissues, where 
there can be considerable variations between individu-
als. A study evaluated the splenic immune responses 
in patients with immune thrombocytopenia (ITP) to 
address the immunomodulatory effects of RTX. The 
authors found marked follicular atrophy and a significant 
reduction in the number of splenic B lymphocytes in ITP 
patients treated with RTX. On the contrary, the number 
of plasma cells was increased in splenic samples from 
ITP patients who did not improve after RTX treatment 
[76]. The latter findings support the concept that the 
long-lived plasma cells, which are not affected by RTX, 
can sustain pathogenic antibody production for a vari-
able time after RTX, thus being responsible for the poor 
or delayed clinical response. Of note, in the same indi-
vidual the depletion’s grade tends to be similar in differ-
ent tissues, suggesting that the extent of B-cell depletion 
achieved may be influenced by individual factors [77]. 
Among these, the antigen modulation, which refers to the 
CD20 endocytosis after binding the antibody, may play 
an important role, through the reduction of the recruit-
ment of Fcγ receptors on effector immune cells [78].
Another cause of incomplete B-cell depletion is the 
induction of anti-RTX antibody response, which may 
influence drug action and clearance rates. This phenome-
non has been described in patients with autoimmune dis-
eases who received a RTX-retreatment. However, most 
large studies found no association between the presence 
of anti-RTX antibodies and clinical outcome [79, 80].
Even though the major part of RTX-immunomodula-
tory effects are accountable to B-cell depletion, evidence 
has proved that RTX also may target both helper and 
cytotoxic T-cells. The effect of RTX on T-cell compart-
ment mainly consists in both the increase of T regula-
tory cells and the normalization of Th1/Th2 ratio, which 
is frequently increased in some autoimmune disorders as 
ITP. In a study in ITP patients, the major T-cell abnor-
malities observed were the increase of Th1/Th2 ratio, the 
over-expression of Fas ligand on Th1 and Th2 cells, the 
over-expression of Bcl-2 mRNA and the expansion of 
oligoclonal T cells in ITP patients compared to controls 
[14]. These abnormalities were reverted in RTX-respond-
ers after 3 and 6  months of treatment, whereas they 
remained unchanged in non-responders. Consistently 
with this findings, a significant increase in the Th1/Treg 
ratio was detected in splenic samples from ITP patients 
who failed RTX therapy compared with controls and to 
ITP patients not treated with RTX [76]. From a theoreti-
cal point of view, these results support the use of RTX 
in autoimmune and lymphoproliferative complications 
of CVID. Indeed, various studies have recently demon-
strated a skewed memory CD4+ T-cell differentiation 
toward a CXCR3+CCR6− TH1 phenotype both in blood 
and lymph nodes in patients with CVID and immune 
dysregulation [28, 29].
Autoimmune cytopenias
Cytopenias, including immune thrombocytopenia (ITP), 
autoimmune hemolytic anemia (AIHA) and autoimmune 
neutropenia (AN), are the most common hematological 
autoimmune disorders in CVID [81]. Autoimmune cyto-
penias (AC) may be the first evidence of immune dysreg-
ulation, preceding the occurrence of recurrent infections 
and even of hypogammaglobulinemia [82]. In the last 
report from the European CVID Registry by the Euro-
pean Society for Immunodeficiencies (ESID), AC were 
found to be correlated with enteropathy, granulomatous 
disease, splenomegaly and splenectomy, low IgA level, 
and later age of onset of CVID, while had been already 
associated with the reduction of IgG class-switched 
B-cells (CD27+IgM−IgD−) in peripheral blood [83, 84]. 
Although the pathogenesis of AC in CVID is not com-
pletely understood, various mechanisms have been pro-
posed: the reduction of T regulatory (Treg) cells, whose 
relevance is supported by the finding of high rates of both 
granulomatous disease and autoimmunity in the subset 
of CVID patients with very low Treg cells [85, 86], and 
the persistent antigenic exposure to microbial antigens, 
which could trigger autoimmunity by molecular mim-
icry [87]. Recently, Romberg et  al. found that patients 
with CVID and AC displayed irregularly shaped hyper-
plastic germinal centers with an increase in numbers of 
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circulating TFH cells correlating with decreased regula-
tory T-cell frequencies and function [88].
ITP is the most common AC in CVID with a 7% to 14%, 
prevalence while the proportion of CVID patients with 
AIHA and AN is 4–7% and 1%, respectively [56]. ITP is 
also the most challenging AC to manage, often requiring 
immunosuppressive combination protocols and multiple 
treatments [89].
The standard treatment of CVID-associated AC con-
sists in the use of glucocorticoids up to at 1  mg/kg 
prednisone-equivalent, associated, if a rapid response 
is required, to high-dose intravenous immunoglobulin 
(IVIG) (1–2 g/kg in 5 days). Rho (D) immunoglobulin is 
an option for non-splenectomized Rh-positive subjects 
who cannot receive glucocorticoid treatment [90]. 
Although the initial response rates are around the 85%, 
relapses are very frequent, thus requiring prolonged 
use of high-dose glucocorticoids [91–93]. Over the past 
decades, splenectomy has been the traditional second 
line approach in non-responders or relapsing patients 
and, behalf the introduction of RTX, up to the 50% of 
CVID-ITP patients required splenectomy as second-
line treatment [19]. The largest multicenter retrospec-
tive study on splenectomy was carried out by the ESID 
in 2013 and reported the outcome of splenectomy in 
45 CVID patients over a 4 decade period [94]. Splenec-
tomy proved to be an effective long-term treatment in 
Fig. 1 Schematic representation of the multiple mechanisms that have been proposed to explain the immunosuppressive effects of RTX. RTX 
is a chimeric  IgG1 monoclonal antibody (mAb) (the Fc domain is humanized, whereas the Fab domain is murine) that targets the CD20 protein 
on human B-cells. RTX depletes B-cells primarily through an antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-mediated 
cytotoxicity (CMC). ADCC occurs through the engagement of Fcγ receptor on NK cells by the Fc domain of RTX. Activated NK cells release perforin 
and granzymes that cause B-cell lysis. CMC occurs through the activation of the complement cascade by the interaction of RTX and CD20, the 
formation of anaphylatoxins (i.e., C5a, C3a) and the membrane attack complex. The Fcγ receptor is also expressed by human macrophages and 
neutrophils. Therefore, RTX can also cause antibody-dependent phagocytosis of B-cells by macrophages and neutrophils. Moreover, RTX can cause 
the apoptosis of B cells through the induction of both CD20 cross-linking on surface membrane and MAP kinase activation. Indeed, apoptotic 
B-cells are cleared by phagocytes, such as macrophages and neutrophils, through Fcγ receptor’s activation. Finally, there is some evidence that RTX 
can decrease Th1 cells and can increase Th2 and Treg cells
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75% of CVID patients with autoimmune cytopenia not 
worsening mortality.
RTX was first used for CVID-related AC, in 2004 [91]. 
After this report, various cases have described the out-
comes of RTX in AC, reporting high response rates (up 
to 90%) but also significant relapses (up to 78%) [92, 93, 
95–99]. In 2011, a multicenter retrospective study inves-
tigated the long-term outcome of RTX in 33 patients 
with CVID-associated refractory AC. RTX was usually 
given at standard dose, namely 375 mg/m2 once a week 
for 4 weeks. The authors found an overall initial response 
rate of 84% (with platelets > 30 × 103/µl or Hb > 10  g/
dl), including 74% complete responses (defined as plate-
lets > 100 × 103/µl or Hb > 12 g/dl). Durable response rate 
(complete response lasting more than 12  months) was 
observed in 59% patients. Major infections were the most 
frequent and severe adverse drug reaction (24.2%, 8/33) 
over a mean follow-up period of 39  months [19]. How-
ever, the incidence of major infections was not different 
from that observed in CVID patients with AC undergo-
ing the first line of treatment, including glucocorticoids 
with or without high-dose IVIG [91].
In conclusion, RTX may be considered an effective 
therapeutic option for CVID-related AC, in particular 
in the subset of patients who cannot receive long-term 
high-dose glucocorticoids or present surgical contrain-
dications (i.e., portal system hemodynamic changes) to 
splenectomy. Moreover, the effectiveness of B-cell deple-
tion suggests that other molecules targeting B-cells (i.e., 
bortezomib, epratuzumab, ibrutinib) may also be effec-
tive in CVID-related AC [100–102].
Granulomatous lymphocytic interstitial lung disease
A subset (5 to 22%) of CVID patients develop granuloma-
tous lymphocytic interstitial lung disease (GLILD) [103–
105]. The ethiopathogenetic features of this disorder are 
not completely understood and its characterization lies 
on both radiological abnormalities and histopathological 
findings [106]. Lymphocytic interstitial pneumonia (LIP), 
follicular bronchitis/bronchiolitis and granulomatous 
inflammation are the predominant histopathologic pat-
terns, whereas the HR-CT finding of scattered nodules 
with areas of consolidation and ground glass, prominent 
on the lower zones, form the main radiographical pic-
tures [107, 108].
Typical symptoms of GLILD are cough and dyspnea, 
while fever and pleuritic chest pain are rare. GLILD is 
frequently associated with splenomegaly, diffuse adenop-
athy, autoimmune cytopenias, and gastrointestinal and 
hepatic disease, thus suggesting a multi-systemic nature 
of the underlying pathogenesis. Various pathogenetic 
hypothesis have been proposed. Pulmonary granuloma-
tous inflammation may develop in response to chronic 
antigenic stimulation, with pulmonary microenviron-
ment preferentially favoring T-cell proliferation with 
a subsequent B-cell recruitment. On the other hand, 
the intrinsic immune dysregulation typical of CVID 
may favor the development of interstitial lung disease, 
as observed in CVID-like monogenic diseases such as 
cytotoxic T lymphocyte associated protein-4 (CTLA-4) 
deficiency and signal transducer and activator of tran-
scription 3 (STAT3) gain-of-function mutations. Finally, 
a relatively high frequency of EBV, HIV and HHV-8 
has been found in lung samples from patients with LIP, 
suggesting that viruses may play a role in triggering the 
lymphocyte infiltrate associated with GLILD [103–108]. 
To date, there is no established standard of care for the 
treatment of patients with CVID and GLILD, nor when 
it is necessary to start the treatment. These are impor-
tant issues, since GLILD has been associated to a poor 
prognostic outcome. An early intervention targeting the 
polyclonal lymphocytic infiltration may reduce the rates 
of disability and mortality. Empirical treatments, includ-
ing glucocorticoids, cyclosporine and infliximab, have 
been used with variable results. In the last 6 years, vari-
ous case reports and small cohort studies have described 
the outcome of RTX, alone or in combination with clas-
sical immunosuppressants, in CVID patients with GLILD 
[62, 109–113].
The largest series included seven patients, who were 
treated with RTX at the weekly dose of 375  mg/m2 for 
4  weeks (repeated at 4–6  month intervals, for 3 or 4 
total courses) and oral azathioprine (1.0–2.0  mg/kg/
day, 18  months duration) [62]. Post-treatment improve-
ment was noted in both lung function (FEV1 and FVC) 
and radiographic findings (pulmonary consolidations, 
ground-glass, nodular opacities and bronchial wall 
thickening). No significant chemotherapy-related com-
plications occurred. Similar results in terms of both 
effectiveness and safety were achieved in 4 case reports 
described between 2015 and 2017, by using the same 
therapeutic protocol including RTX and azathioprine 
[109–112]. In 2017 Jolles et  al. described the use of 
2-[(18)F]-fluoro-2-deoxy-d-glucose positron emission 
tomography and computed tomography (FDG PET-
CT) scanning for the monitoring of response in a CVID 
patient with GLILD, treated with 2 infusions of RTX at 
dose of 1 g (with an interval of 1 month) in combination 
with long-term standard-dose (1–2  g/day) mycophe-
nolate [113]. An almost complete resolution of the 
previously identified high metabolic activity and a nor-
malization in lymph node size and lung architecture were 
observed. Recently, a RTX monotherapy was evaluated in 
3 CVID naive patients: RTX was followed by an improve-
ment in the severity and extent of both interstitial lung 
lesions and mediastinal adenopathy in all patients [20].
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Collectively, these data confirm the effectiveness and 
safety of RTX in CVID-associated GLILD. On the other 
hand, a recent Consensus Statement on the manage-
ment of GLILD in CVID, carried out by the British Lung 
Foundation/United Kingdom Primary Immunodeficiency 
Network, reports a 91% consensus on the use of gluco-
corticoids alone as first-line treatment [63]. Definitively, 
there is still a lack of longitudinal data on the long-term 
outcome and the impact on overall survival of the various 
therapeutic agents.
Non‑malignant lymphoproliferation and other conditions
A number of small series and case reports provide 
information about the effectiveness of RTX in various 
immune-mediated manifestations that are thought to 
be the result of the complex immune dysregulation of 
CVID. Salzer et  al. described the successful outcome of 
RTX (375  mg/m2 administered weekly 4 times) to treat 
the systemic inflammatory response and lymphoprolif-
erative disorder associated with EBV persistent replica-
tion in a pediatric patient with monogenic-CVID due to 
an autosomal recessive CD27 deficiency [114]. A com-
parable outcome was obtained, with the same RTX dose 
in combination with glucocorticoids, for an EBV-related 
lymphoproliferation in a patient with a monogenic form 
of CVID due to a frameshift mutation in the NFKB1 gene 
leading to NF-κB1 haploinsufficiency [115]. Similarly, 
RTX efficacy was reported in an adult patients with mul-
tiple monoclonal lymphoproliferative lesions [116].
Also granulomatous manifestations other than GLILD 
have been treated with RTX. A retrospective analysis of 
59 CVID patients with granulomatous manifestations 
from the French DEFI cohort, found that standard dose 
RTX in combination with glucocorticoids, used in three 
patients, led to one complete and two partial responses 
of granulomatous lymph nodes and liver infiltrates [117].
Finally, the successful use of RTX have been reported 
in single cases of ANCA-associated vasculitis, Takayasu 
arteritis, renal granuloma, intra-cranial granulomata, 
bronchus-associated lymphoid tissue hyperplasia and 
cerebellar inflammatory lesions in patients with CVID 
[118–123].
Conclusion
There is compelling evidence that autoimmune and lym-
phoproliferative disorders strongly affect the long-term 
outcome of CVID patients. The management of these 
complications often require multiple lines of treatment 
including various immunosuppressive drugs. Although 
glucocorticoids remain the first line of treatment for all 
the complications of CVID associated with the immune-
dysregulation, over the last 5–10 years, RTX has proven to 
be an effective and relatively safe second-line therapy for 
both autoimmune and non-malignant lymphoproliferative 
manifestations. To date, there are no data on the long-term 
efficacy and side effects of RTX and other second-line ther-
apeutic options. Further trials evaluating the head-to-head 
comparison between RTX and other second-line therapeu-
tic options are needed to optimize the management strate-
gies of non-infectious complications of CVID.
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